Parathyroid hormone

Clinical Reviews in Bone and Mineral Metabolism

Volumn 3, Issue 1, 2005, Pages 31-38

  Koval, Peter ^a   Seaton, Terry L ^b  

^a Moses Cone Family Practice   (United States)

^b ST LOUIS COLLEGE OF PHARMACY   (United States)

Author keywords

Bone mineral density; Forteo; Fracture; Osteoporosis; Parathyroid hormone; Teriparatide

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; DIGOXIN; ESTROGEN; FUROSEMIDE; GLUCOCORTICOID; HYDROCHLOROTHIAZIDE; NAFARELIN; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; PLACEBO; RALOXIFENE; RECOMBINANT PARATHYROID HORMONE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TESTOSTERONE; VITAMIN D;

ANGINA PECTORIS; AREA UNDER THE CURVE; ARTHRALGIA; ASTHENIA; BONE DENSITY; CANCER RISK; CLINICAL TRIAL; CONSTIPATION; CORTICOSTEROID INDUCED OSTEOPOROSIS; COUGHING; DEPRESSION; DIARRHEA; DIZZINESS; DRUG CONTRAINDICATION; DRUG COST; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SAFETY; DYSPEPSIA; DYSPNEA; ENDOMETRIOSIS; EPIPHYSIS; FRACTURE REDUCTION; GASTROINTESTINAL DISEASE; HIGH RISK PATIENT; HUMAN; HYPERCALCEMIA; HYPERTENSION; INJECTION PAIN; INSOMNIA; LEG CRAMP; NAUSEA; NECK PAIN; NONHUMAN; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; OSTEOSARCOMA; PAGET BONE DISEASE; PAIN; PHARYNGITIS; PNEUMONIA; POSTMENOPAUSE; RADIATION EXPOSURE; REVIEW; RHINITIS; RISK REDUCTION; SIDE EFFECT; SWEATING; SYNCOPE; TOOTH DISEASE; TREATMENT FAILURE; VERTEBRA FRACTURE; VERTIGO; VOMITING;

EID: 26244454930     PISSN: 15348644     EISSN: None     Source Type: Journal    
DOI: 10.1385/bmm:3:1:031     Document Type: Review

References (26)

1. Forteo (teriparatide [rDNA origin] injection) [package insert]. 2004 Product information. Indianapolis, IN: Eli Lilly and Co.
2. Deal C. 2004 The use of intermittent human parathyroid hormone as a treatment for osteoporosis. Curr Rheumatol Rep 1:49-58.
3. Jiang Y, Zhao JJ, Mitlak BH, Wang O, Genant HK, Eriksen EF. 2003 Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. J Bone Min Res 18:1932-1941.
4. Quattrrocchi E, Kourlas H. 2004 Teriparatide: a review. Clin Ther 26:841-854.
5. Neer RM, Arnaud CD, Zanchetta JR, et al. 2001 Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434-1441.
6. Body JJ, Gaich GA, Sheele WH, et al. 2002 A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 87:4528-4535.
7. Brown TER. 2003 Osteoporosis: a pharmacotherapy update. J Pharm Pract 16:164-169.
8. Hodsman AB, Hanley DA, Ettinger MP, Bolognese JF, Metcalf AJ, Lindsay R. 2003 Efficacy and safety of human parathyroid hormone (1-84) in increasing bone mineral density in postmenopausal osteoporosis. J Clin Endocrinol Metab 88:5212-5220.
9. Lin JT, Lane JM. 2004 Osteoporosis: a review. Clin Orthoped Rel Res 425:126-134.
10. Orwoll ES, Scheele WH, Paul S, et al. 2003 The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Min Research 18:9-17.
11. Cosman F, Nieves J, Woelfert L, Shen, Lindsay R. 1998 Alendronate does not block the anabolic effect of PTH in postmenopausal osteoporotic women. J Bone Min Res 13:1051-1055.
12. Black DM, Greenspan SL, Ensrad KE, et al. 2003 The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 349:1207-1215.
13. Finkelstein JS, Hayes A, Hunzelman JL, Wyland JJ, Lee Hang, Neer RM. 2003 The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Eng J Med 349:1216-1226.
14. Reeve J, Mitchell A, Tellez M, et al. 2001 Treatment with parathyroid peptides and estrogen replacement for severe postmenopausal vertebral osteoporosis: Prediction of long-term responses in spine and femur. J Bone Min Metab 19:102-114.
15. Ettinger B, San Martin J, Crans G, Pavo I. 2004 Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Min Res 19:745-751.
16. Rittmaster RS, Bolognese M, Ettinger M, et al. 2000 Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J Clin Endocrinol Metab 85:2129-2134.
17. Lane NE, Sanchez S, Modin GW, Genant HK, Pierini E, Arnaud CD. 1998 Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. J Clin Invest 102:1627-1633.
18. Lane NE, Sanchez S, Genant HK, Jenkins DK, Arnaud CD. 2000 Short-term increases in bone turnover markers predict parathyroid hormone-induced spinal bone mineral density gains in postmenopausal women with glucocorticoid-induced osteoporosis. Osteoporosis Int 11:434-442.
19. Rehman Q, Lang TF, Arnaud CD, Modin GW, Lane NE. 2003 Daily treatment with parathyroid hormone is associated with an increase in vertebral cross-sectional area in postmenopausal women with glucocorticoid-induced osteoporosis. Osteoporosis Int 14:77-81.
20. Lane NE, Sanchez S, Modin GW, Genant HK, Pierini E, Arnaud CD. 2000 Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: results of a randomized controlled clinical trial. J Bone Min Res 15:944-951.
21. Finkelstein JS, Klibanski A, Arnold A, Toth TL, Homstein MD, Neer RM. 1998 Prevention of estrogen deficiency-related bone loss with human parathyroid hormone(1-34): a randomized controlled trial. JAMA 280:1067-1073.
22. AACE Osteoporosis Task Force. 2003 American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003. Endocrine Pract 9:544-564. Also available at: http://www.aace.com/ clin/guidelines/osteoporosis2001Revised.pdf (accessed 10/7/04).
23. Brown JP, Josse RG. 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ 167(10 Suppl):S1-S34.
24. National Osteoporosis Foundation. 2003 Physician's guide to prevention and treatment of osteoporosis. http://www.nof.org/professionals/clinical.htm (accessed 10/7/04).
25. NPS Pharmaceuticals. http://www.npsp.com/drug_development/dd_preos.php (accessed 10/7/04).
26. Pharmaceutical Research and Manufacturers of America. http://www.phrma.org/newmedicines/newmedsdb/drugs.cfm (accessed 10/7/04).